Please assess the completion status of the following clinical trial:

Trial Title: Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key inclusion criteria:~* Patients had advanced (locoregionally recurrent or metastatic) breast cancer not amenable to curative therapy~* Patients were premenopausal or perimenopausal at the time of study entry~* Patients who had received (neo) adjuvant therapy for breast cancer were eligible~* Patients had a histologically and/or cytologically confirmed diagnosis of estrogen-receptor positive and/or progesterone receptor positive breast cancer~* Patients had HER2-negative breast cancer~* Patients must have either had measurable disease or If no measurable disease was present, then at least one predominantly lytic bone lesion~* Patients had an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1~* Patients had adequate bone marrow and organ function~Key exclusion criteria:~* Patients who had received a prior CDK4/6 inhibitor~* Patients were postmenopausal~* Patients who currently had inflammatory breast cancer at screening.~* Patients who had received any prior hormonal anti-cancer therapy for advanced breast cancer, except for ≤ 14 days of tamoxifen or NSAI ± goserelin for advanced breast cancer prior to randomization.~* Patients had a concurrent malignancy or malignancy within 3 years of randomization, with the exception of adequately treated basal cell skin carcinoma, squamous cell skin carcinoma, non-melanomatous skin cancer or curatively resected cervical cancer.~* Patients with CNS metastases.~* Patients had active cardiac disease or a history of cardiac dysfunction~* Patients were currently using other antineoplastic agents~* Patients were pregnant or nursing or physiologically capable of becoming pregnant and not using highly effective contraception.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 59 Years
- Healthy Volunteers: f

Study Arms:
- Ribociclib + NSAI/tamoxifen + goserelin (Type: EXPERIMENTAL): Ribociclib 600 mg daily oral (3 weeks on/ 1 week off) in combination with NSAI or tamoxifen (tamoxifen 20 mg daily oral or letrozole 2.5 mg daily oral or anastrozole 1 mg daily oral) and goserelin 3.6 mg subcutaneous injection (once every 28 days)
- Placebo + NSAI/tamoxifen + goserelin (Type: PLACEBO_COMPARATOR): Placebo daily oral (3 weeks on/ 1 week off) in combination with NSAI or tamoxifen (tamoxifen 20 mg daily oral or letrozole 2.5 mg daily oral or anastrozole 1 mg daily oral) and goserelin 3.6 mg subcutaneous injection (once every 28 days).~Participants were unblinded once the final OS analysis was conducted and after the implementation of protocol amendment 6 (16-Jul-2019) and were given the option to crossover to treatment with ribociclib +NSAI/tamoxifen + goserelin.

Based on this trial design, predict the completion outcome and termination type (if applicable).